Our latest report takes an in-depth look at the patent landscape surrounding BeiGene's Tislelizumab. This humanized IgG4 monoclonal antibody targeting PD-1 has received market approval in China and is increasingly utilized for the treatment of non-small cell lung cancer and hepatocellular carcinoma.

The report provides a detailed guide for monoclonal antibody patent research, highlighting key factors including:

- Systematic patent searching and screening to identify relevant intellectual property 
- In-depth analysis of clinical data to inform strategic decision-making 
- Insights into infringement analysis, biosimilar development, and investment decisions 

By meticulously navigating each stage of the patent research process, pharmaceutical companies can gain a competitive edge and drive the advancement of monoclonal antibody therapies.